Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.

BMC cancer - 9 Nov 2015

Massink Maarten P G, Kooi Irsan E, Martens John W M, Waisfisz Quinten, Meijers-Heijboer Hanne

Abstract excerpt

BACKGROUND: CHEK2*1100delC is a moderate-risk breast cancer susceptibility allele with a high prevalence in the Netherlands. We performed copy number and gene expression profiling to investigate whether CHEK2*1100delC breast cancers harbor characteristic genomic aberrations, as seen for BRCA1 mutated breast cancers. METHODS: We performed high-resolution SNP array and gene expression profiling of 120 familial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Genomics

Share to Loss of Heterozygosity

Share to Netherlands

Share to Sequence Deletion

Source

Open in PubMed Open full text

Identifiers

PMID: 26553136
DOI: 10.1186/s12885-015-1880-y
PMCID: PMC4640207

Genes

CHEK2
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.PMID 26553136Read ↗

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.Semantic proximity Read ↗

Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.Semantic proximity Read ↗

Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.Semantic proximity Read ↗

Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patientsSemantic proximity Read ↗

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the <i>CHEK2*1100delC</i> Germline MutationSemantic proximity Read ↗

Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association ConsortiumSemantic proximity Read ↗

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.Semantic proximity Read ↗

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.Semantic proximity Read ↗

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.Semantic proximity Read ↗

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.Semantic proximity Read ↗

No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors.Semantic proximity Read ↗

Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.